- Home
- PMEC vs PASG Comparison
PMEC vs PASG Comparison
Compare PMEC & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | PASG |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 26.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PMEC | PASG |
|---|---|---|
| Price | $0.69 | $7.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 190.3K | 31.8K |
| Earning Date | 07-24-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.28 |
| 52 Week High | $2.44 | $20.00 |
Technical Indicators
Market Signals| Indicator | PMEC | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 35.29 |
| Support Level | $0.60 | $6.71 |
| Resistance Level | $1.11 | $7.72 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 26.07 | 10.93 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.